Epigenetics Drugs and Diagnostic Technologies Market Size, Share & Trends Analysis Report By Type of Therapy (HDAC, DNMT), By Application (Oncology, Non-oncology), And Segment Forecasts, 2019 - 2025

Published: Jan, 2019 | Pages: 110 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global epigenetics drugs and diagnostic technologies market size is expected to reach USD 22.05 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a 19.7% CAGR during the forecast period. Rising incidence of cancer with epigenetic modification base is projected to drive the market growth.

Diagnostic firms are focused on developing new treatments such as antibodies specific for detection of epigenetic modifications and advanced kits for effective detection of biomarkers. It is likely to encourage pharmaceutical firms to partner for development of new advanced treatments which will further accelerate the market growth.

Presence of a large number of products under clinical trials and their projected commercialization is likely to boost the market. For instance, Eli Lilly's Ramucirumab have been approved by the U.S. Food and Drug Administration (FDA) to be used in combination with Folfiri for the treatment of metastatic colorectal cancer.

Introduction of technologically advanced products in this space is mostly focused on detection of methylation markers associated with cancer development. For example, Epigenomics introduced Epi proLung BL Reflex Assay which helps in lung cancer diagnosis by determining methylation of SHOX2 biomarker gene.

Further key findings from the report suggest:

•	Reagents is expected to account for the largest market share of over USD 7,058.4 million by 2025 owing to increasing R&D in epigenetics. The kits segment is expected to be in more demand over the forecast period with at CAGR of 20.0% due to need for rapid and accurate detection techniques

•	DNA methylation held the major market share of the technology segment in terms of revenue over 47.1% in 2017 owing to rising adoption coupled with development of technological advanced products such as Methylation Sensitive PCR (MSP)

•	DNMT inhibitors was the largest segment in 2017 due to the factors such as wide availability of these inhibitors and generics in most regions

•	Oncology was the largest revenue generating segment owing to the factors such as growing prevalence of cancer and strong product pipeline

•	North America was observed to be the major region for epigenetics market accounting for over 39.3% market share due to high prevalence of cancer, increasing R&D funding, collaborations among big pharmaceutical companies for development of improved treatments, and patient awareness

•	Asia Pacific is projected to showcase lucrative CAGR of 22.1% owing to a high number of cancer, diabetes, and other chronic disorders with parallel unmet medical needs

•	Major players operating in the epigenetics drugs and diagnostic technologies market include Zymo research; CellCentric Ltd; Thermo Fisher Scientific;Illumina; Abcam; Eisai Co. Ltd; Diagenode; Merck; Syndax Pharmaceuticals, Inc.; Qiagen; Chroma Therapeutics Ltd; Novartis International AG; Oncolys Biopharma Inc.; Sigma-Aldrich Corporation; and Valirx Plc. Widespread R&D activities and clinical studies are expected to boost the market growth over the forecast period.

 Table Of Content

Chapter 1 Research Methodology
                  1.1 Information procurement
                  1.2 Information or data analysis
                  1.3 Market formulation & validation
Chapter 2 Executive Summary
                  2.1 Market snapshot
Chapter 3 Market Variables, Trends & Scope
                  3.1 Market segmentation & scope
                  3.2 Market driver analysis
                      3.2.1. Increasing prevalence of target diseases
                      3.2.2 Growing global geriatric population
                      3.2.3 Increasing collaborations between biotechnology companies, pharmaceutical companies, and academic research institutes
                      3.2.4 Presence of funding programs to promote and support research & development
                      3.2.5 Technological advancements
                  3.3 Market restraint analysis
                      3.3.1 Inefficiency in identification and validation of biomarkers
                      3.3.2 Presence of complex regulatory framework
                  3.4 Penetration & growth prospect mapping
                  3.5 Epigenetics drugs and diagnostics technologies market - SWOT analysis, by factor (political & legal, economic and technological)
                  3.6 Industry analysis - Porter's
                  3.7 Epigenetics drugs and diagnostics technologies market -Pipeline overview
Chapter 4 Epigenetics Drugs and Diagnostics Technologies Market: Product Estimates & Trend Analysis
                  4.1 Epigenetics drugs and diagnostics technologies market: Product movement analysis
                  4.2 Reagents
                      4.2.1 Reagents market estimates and forecasts, 2014 - 2025 (USD Million)
                  4.3 Kits
                      4.3.1 Kits market estimates and forecasts, 2014 - 2025 (USD Million)
                      4.3.2 ChIP sequencing kit
                          4.3.2.1 ChIP sequencing kit market estimates and forecasts, 2014 - 2025 (USD Million)
                      4.3.3 Whole-genomic amplification kit
                          4.3.3.1 Whole-genomic amplification kit market estimates and forecasts, 2014 - 2025 (USD Million)
                      4.3.4 Bisulfite conversion kit
                          4.3.4.1 Bisulfite conversion kit market estimates and forecasts, 2014 - 2025 (USD Million)
                      4.3.5 RNA sequencing kit
                          4.3.5.1 RNA sequencing Kit market estimates and forecasts, 2014 - 2025 (USD Million)
                      4.3.6 Others
                          4.3.6.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
                  4.4 Instruments 
                      4.4.1 Instruments market estimates and forecasts, 2014 - 2025 (USD Million)
                  4.5 Enzymes 
                      4.5.1 Enzymes market estimates and forecasts, 2014 - 2025 (USD Million)
                  4.6 Services 
                      4.6.1 Services market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 Epigenetics Drugs and Diagnostics Technologies Market: Technology Estimates & Trend Analysis
                  5.1 Epigenetics drugs and diagnostics technologies market: Technology movement analysis
                  5.2 DNA methylation 
                      5.2.1 DNA methylation market estimates and forecasts, 2014 - 2025 (USD Million)
                  5.3 Histone methylation 
                      5.3.1 Histone methylation market estimates and forecasts, 2014 - 2025 (USD Million)
                  5.4 Histone acetylation
                      5.4.1 Histone acetylation market estimates and forecasts, 2014 - 2025 (USD Million)
                  5.5 Large non-coding RNA 
                      5.5.1 Large non-coding RNA market estimates and forecasts, 2014 - 2025 (USD Million)
                  5.6 MicroRNA modification 
                      5.6.1 MicroRNA modification market estimates and forecasts, 2014 - 2025 (USD Million)
                  5.7 Chromatin structures 
                      5.7.1 Chromatin structures market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 6 Epigenetics Drugs and Diagnostics Technologies Market: Types of Therapies Estimates & Trend Analysis
                  6.1 Epigenetics drugs and diagnostics technologies market: Types of therapies movement analysis
                  6.2 Histone deacetylase (HDAC) inhibitors
                      6.2.1 HDAC inhibitors market estimates and forecasts, 2014 - 2025 (USD Million)
                  6.3 DNA methyltransferase (DNMT) inhibitors
                      6.3.1 DNMT inhibitors market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 7 Epigenetics Drugs and Diagnostics Technologies Market: Application Estimates & Trend Analysis
                  7.1 Epigenetics drugs and diagnostics technologies market: Application movement analysis
                  7.2 Oncology
                      7.2.1 Oncology market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.2.2 Solid tumors
                          7.2.2.1 Solid tumors market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.2.3 Liquid tumors
                          7.2.3.1 Liquid tumors market estimates and forecasts, 2014 - 2025 (USD Million)
                  7.3 Non-oncology disorders
                      7.3.1 Non-oncology disorders market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.3.2 Inflammatory diseases
                          7.3.2.1 Inflammatory diseases market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.3.3 Metabolic diseases
                          7.3.3.1 Metabolic diseases market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.3.4 Infectious diseases
                          7.3.4.1 Infectious diseases market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.3.5 Cardiovascular diseases
                          7.3.5.1 Cardiovascular diseases market estimates and forecasts, 2014 - 2025 (USD Million)
                      7.3.6 Others
                          7.3.6.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 8 Epigenetics Drugs and Diagnostics Technologies Market: Regional Estimates & Trend Analysis
                  8.1 Epigenetics drugs and diagnostics technologies market share by region, 2017 & 2025
                  8.2 North America
                      8.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.2.2 U.S.
                          8.2.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.2.3 Canada
                          8.2.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                  8.3 Europe
                      8.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.3.2 Germany
                          8.3.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.3.3 U.K.
                          8.3.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                  8.4 Asia Pacific
                      8.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.4.2 Japan
                          8.4.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.4.3 China
                          8.4.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.4.4 India
                          8.4.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                  8.5 Latin America
                      8.5.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.5.2 Brazil
                          8.5.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.5.3 Mexico
                          8.5.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                  8.6 MEA
                      8.6.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                      8.6.2 South Africa
                          8.6.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 9 Competitive Landscape
                  9.1 Strategy Framework
                  9.2 Illumina, Inc.
                      9.2.1 Company overview
                      9.2.2 Financial performance
                      9.2.3 Product benchmarking
                      9.2.4 Strategic initiatives
                  9.3 Merck Sharp & Dohme Corp
                      9.3.1 Company overview
                      9.3.2 Financial performance
                      9.3.3 Product benchmarking
                      9.3.4 Strategic initiatives
                  9.4 Qiagen
                      9.4.1 Company overview
                      9.4.2 Financial performance
                      9.4.3 Product benchmarking
                      9.4.4 Strategic initiatives
                  9.5 F. Hoffmann-La Roche Ltd.
                      9.5.1 Company overview
                      9.5.2 Financial performance
                      9.5.3 Product benchmarking
                      9.5.4 Strategic initiatives
                  9.6 Eisai Co., Ltd.
                      9.6.1 Company overview
                      9.6.2 Financial performance
                      9.6.3 Product benchmarking
                      9.6.4 Strategic initiatives
                  9.7 Novartis AG
                      9.7.1 Company overview
                      9.7.2 Financial performance
                      9.7.3 Product benchmarking
                      9.7.4 Strategic initiatives
                  9.8 Abcam plc
                      9.8.1 Company overview
                      9.8.2 Financial performance
                      9.8.3 Product benchmarking
                      9.8.4 Strategic initiatives
                  9.9 Diagenode Diagnostics
                      9.9.1 Company overview
                      9.9.2 Financial performance
                      9.9.3 Product benchmarking
                      9.9.4 Strategic initiatives
                  9.10 Thermo Fisher Scientific, Inc.
                      9.10.1 Company overview
                      9.10.2 Financial performance
                      9.10.3 Product benchmarking
                      9.10.4 Strategic initiatives
                  9.11 Active Motif
                      9.11.1 Company overview
                      9.11.2 Financial performance
                      9.11.3 Product benchmarking
                      9.11.4 Strategic initiatives
                  9.12 Zymo Research Corporation
                      9.12.1 Company overview
                      9.12.2 Financial performance
                      9.12.3 Product benchmarking
                      9.12.4 Strategic initiatives
                  9.13 CellCentric
                      9.13.1 Company overview
                      9.13.2 Product benchmarking
                      9.13.3 Strategic initiatives
                  9.14 Chroma Therapeutics Ltd.
                      9.14.1 Company overview
                      9.14.2 Financial performance
                      9.14.3 Product benchmarking
                      9.14.4 Strategic initiatives
                  9.15 Oncolys BioPharma Inc.
                      9.15.1 Company overview
                      9.15.2 Financial performance
                      9.15.3 Product benchmarking
                      9.15.4 Strategic initiatives
                  9.16 Syndax
                      9.16.1 Company overview
                      9.16.2 Financial performance
                      9.16.3 Product benchmarking
                      9.16.4 Strategic initiatives
                  9.17 Valirx
                      9.17.1 Company overview
                      9.17.2 Financial performance
                      9.17.3 Product benchmarking
                      9.17.4 Strategic initiatives
                  9.18 Sigma-Aldrich Corporation (Merck KGaA)
                      9.18.1 Company overview
                      9.18.2 Financial performance
                      9.18.3 Product benchmarking
                      9.18.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 Global cancer cases, 2016
TABLE 3 Some major collaboration in epigenetic market
TABLE 4 List of key organizations funding epigenetics related R&D worldwide
TABLE 5 Pipeline and new product development analysis.
TABLE 6 North America epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 7 North America epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 8 North America epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 9 North America epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 10 U.S. epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 11 U.S. epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 12 U.S. epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 13 U.S. epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 14 Canada epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 15 Canada epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 16 Canada epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 17 Canada epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 18 Europe epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 19 Europe epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 20 Europe epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 21 Europe epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 22 Germany epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 23 Germany epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 24 Germany epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 25 Germany epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 26 U.K. epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 27 U.K. epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 28 U.K. epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 29 U.K. epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 30 Asia Pacific epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 31 Asia Pacific epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 32 Asia Pacific epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 33 Asia Pacific epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 34 Japan epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 35 Japan epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 36 Japan epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 37 Japan epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 38 China epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 39 China epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 40 China epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 41 China epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 42 India epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 43 India epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 44 India epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 45 India epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 46 Latin America epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 47 Latin America epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 48 Latin America epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 49 Latin America epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 50 Brazil epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 51 Brazil epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 52 Brazil epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 53 Brazil epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 54 Mexico epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 55 Mexico epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 56 Mexico epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 57 Mexico epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 58 MEA epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 59 MEA epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 60 MEA epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 61 MEA epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 62 South Africa epigenetics drugs and diagnostics technologies market estimates and forecasts, by product, 2014 - 2025 (USD Million)
TABLE 63 South Africa epigenetics drugs and diagnostics technologies market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 64 South Africa epigenetics drugs and diagnostics technologies market estimates and forecasts, by types of therapies, 2014 - 2025 (USD Million)
TABLE 65 South Africa epigenetics drugs and diagnostics technologies market estimates and forecasts, by application, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Global population by age group, 2000 - 2050 (in billion)
FIG. 12 Population of age 60 years and above, by region (2015 & 2020)
FIG. 13 Market restraint relevance analysis (Current & future impact)
FIG. 14 Epigenetics key opportunities prioritized
FIG. 15 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 16 Porter's Five Forces Analysis
FIG. 17 Epigenetics drugs and diagnostics technologies market product outlook key takeaways
FIG. 18 Epigenetics drugs and diagnostics technologies market: Product movement analysis
FIG. 19 Reagents market, 2014 - 2025 (USD Million)
FIG. 20 Kits market, 2014 - 2025 (USD Million)
FIG. 21 ChIP sequencing kit market, 2014 - 2025 (USD Million)
FIG. 22 Whole-genomic amplification kit market, 2014 - 2025 (USD Million)
FIG. 23 Bisulfite conversion kit market, 2014 - 2025 (USD Million)
FIG. 24 RNA sequencing kit market, 2014 - 2025 (USD Million)
FIG. 25 Others kit market, 2014 - 2025 (USD Million)
FIG. 26 Instruments market, 2014 - 2025 (USD Million)
FIG. 27 Enzymes market, 2014 - 2025 (USD Million)
FIG. 28 Services market, 2014 - 2025 (USD Million)
FIG. 29 Epigenetics drugs and diagnostics technologies market technology outlook key takeaways
FIG. 30 Epigenetics drugs and diagnostics technologies market: Technology movement analysis
FIG. 31 DNA methylation market, 2014 - 2025 (USD Million)
FIG. 32 Histone methylation market, 2014 - 2025 (USD Million)
FIG. 33 Histone acetylation market, 2014 - 2025 (USD Million)
FIG. 34 Large non-coding RNA market, 2014 - 2025 (USD Million)
FIG. 35 MicroRNA modification market, 2014 - 2025 (USD Million)
FIG. 36 Chromatin structures market, 2014 - 2025 (USD Million)
FIG. 37 Epigenetics drugs and diagnostics technologies market types of therapies outlook key takeaways
FIG. 38 Epigenetics drugs and diagnostics technologies market: Types of therapies movement analysis
FIG. 39 HDAC inhibitors market, 2014 - 2025 (USD Million)
FIG. 40 DNMT inhibitors market, 2014 - 2025 (USD Million)
FIG. 41 Epigenetics drugs and diagnostics technologies market application outlook key takeaways
FIG. 42 Epigenetics drugs and diagnostics technologies market: Application movement analysis
FIG. 43 Oncology market, 2014 - 2025 (USD Million)
FIG. 44 Solid tumors market, 2014 - 2025 (USD Million)
FIG. 45 Liquid tumors market, 2014 - 2025 (USD Million)
FIG. 46 Non-oncology disorders market, 2014 - 2025 (USD Million)
FIG. 47 Inflammatory diseases market, 2014 - 2025 (USD Million)
FIG. 48 Metabolic diseases market, 2014 - 2025 (USD Million)
FIG. 49 Infectious diseases market, 2014 - 2025 (USD Million)
FIG. 50 Cardiovascular diseases market, 2014 - 2025 (USD Million)
FIG. 51 Others market, 2014 - 2025 (USD Million)
FIG. 52 Regional market place: Key takeaways
FIG. 53 Epigenetics drugs and diagnostics technologies market: Regional movement analysis
FIG. 54 North America epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 55 U.S. epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 56 Canada epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 57 Europe epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 58 Germany epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 59 U.K. epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 60 Asia Pacific epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 61 Japan epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 62 China epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 63 India epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 64 Latin America epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 65 Brazil epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 66 Mexico epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 67 MEA epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 68 South Africa epigenetics drugs and diagnostics technologies market, 2014 - 2025 (USD Million)
FIG. 69 Strategy framework